Atlas Trials

A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

Clinical trial NCT00668837 · COMPLETED

Trial details

NCT number
NCT00668837
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2004-02-01
Enrollment
407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.